XRAY:NSD-Dentsply Sirona Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 17.26

Change

-6.72 (-28.02)%

Market Cap

USD 4.76B

Volume

0.03B

Analyst Target

USD 48.77
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform. It also provides endodontic products consisting of motorized endodontic handpieces, files, sealers, irrigation needles, and other tools that support root canal procedures; restorative products, including dental ceramics, crowns, and veneers; and preventative products, such as curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, and impression materials. In addition, the company offers SureSmile and Byte aligner solutions; VPro/HyperByte, a high-frequency vibration technology device; SureSmile Simulator, which creates a 3D visualization of a patient's outcome; and Byte Plus for treatment planning. Further, it provides dental implants, digital dentures, crown and bridge porcelain products, bone regenerative and restorative solutions, treatment planning software, and educational programs; dental prosthetics; urology catheters; and other health-related consumables. The company serves professional dental and consumable medical device markets through third-party distributors. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

+8.73 (+1.69%)

USD 180.35B
COO The Cooper Companies, Inc. Com..

-0.45 (-0.43%)

USD 20.95B
HOLX Hologic Inc

-1.20 (-1.49%)

USD 19.12B
ALGN Align Technology Inc

-2.67 (-1.19%)

USD 16.59B
RGEN Repligen Corporation

-2.05 (-1.40%)

USD 7.52B
MMSI Merit Medical Systems Inc

-0.51 (-0.50%)

USD 5.76B
ICUI ICU Medical Inc

-0.46 (-0.26%)

USD 4.17B
AZTA Azenta Inc

-1.02 (-2.19%)

USD 2.28B
LMAT LeMaitre Vascular Inc

-0.64 (-0.63%)

USD 2.00B
ATRC AtriCure Inc

-0.26 (-0.69%)

USD 1.82B

ETFs Containing XRAY

HBD:CA BetaPro Gold Bullion 2x D.. 6.53 % 1.52 %

-0.19 (0%)

CAD 1.99M
HND:CA BetaPro Natural Gas 2x Da.. 6.04 % 1.52 %

+3.27 (+0%)

CAD 0.06B
MVUS:SW 3.32 % 0.00 %

N/A

N/A
SPMV:SW 3.32 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -51.50% 17% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.50% 17% F 14% F
Trailing 12 Months  
Capital Gain -36.66% 21% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.66% 21% F 18% F
Trailing 5 Years  
Capital Gain -69.94% 11% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.94% 11% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -6.45% 30% F 26% F
Dividend Return -5.40% 33% F 26% F
Total Return 1.05% 60% D- 27% F
Risk Return Profile  
Volatility (Standard Deviation) 30.87% 77% C+ 61% D-
Risk Adjusted Return -17.50% 33% F 25% F
Market Capitalization 4.76B 84% B 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector